BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes
Year: 2022
Type: article
Abstract: Polycomb repressive epigenetic complexes are recurrently dysregulated in cancer. Unlike polycomb repressive complex 2 (PRC2), the role of PRC1 in oncogenesis and therapy resistance is not well-defined. Here, we demonstrate that highly recurrent mutations of the PRC1 subunits BCOR and BCORL1 in leukemia disrupt assembly of a noncanonical PRC1.1 complex, thereby selectively unlinking the RING-PCGF enzymatic core from the chromatin-targeting auxiliary subcomplex. As a result, BCOR-mutated PRC1.1 is localized to chromatin but lacks repressive activity, leading to epigenetic reprogramming and transcriptional activation at target loci. We define a set of functional targets that drive aberrant oncogenic signaling programs in PRC1.1-mutated cells and primary patient samples. Activation of these PRC1.1 targets in BCOR-mutated cells confers acquired resistance to treatment while sensitizing to targeted kinase inhibition. Our study thus reveals a novel epigenetic mechanism that explains PRC1.1 tumor-suppressive activity and identifies a therapeutic strategy in PRC1.1-mutated cancer. SIGNIFICANCE: We demonstrate that BCOR and BCORL1 mutations in leukemia unlink PRC1.1 repressive function from target genes, resulting in epigenetic reprogramming and activation of aberrant cell signaling programs that mediate treatment resistance. Our study provides mechanistic insights into the pathogenesis of PRC1.1-mutated leukemia that inform novel therapeutic approaches. This article is highlighted in the In This Issue feature, p. 85.
Source: Blood Cancer Discovery
Authors: Eva J. Schaefer, Helen C. Wang, Hannah Q. Karp, Clifford A. Meyer, Paloma Cejas, Micah D. Gearhart, Emmalee R. Adelman, Iman Fares, Annie Apffel, Klothilda Lim, Yingtian Xie, Christopher J. Gibson, Monica Schenone, H. Moses Murdock, Eunice S. Wang, Lukasz P. Gondek, Martin P. Carroll, Rahul S. Vedula, Eric S. Winer, Jacqueline S. Garcia, Richard M. Stone, Marlise R. Luskin, Steven A. Carr, Henry W. Long, Vivian J. Bardwell, Maria E. Figueroa, R. Coleman Lindsley
Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Minnesota, Masonic Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Broad Institute, Massachusetts Institute of Technology, Roswell Park Comprehensive Cancer Center, Johns Hopkins University, University of Pennsylvania
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: Dana-Farber Cancer Institute, Edward P. Evans Foundation, Deutsche Forschungsgemeinschaft, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Systems Biology of Bone Marrow Failure and MDS for Precision Medicine, Control of Trophoblast Differentiation in Placental Development, G6919225830, Determining the Role of BCOR Mutations in Myeloid Malignancies, Development of Novel Therapeutic Strategies in Human Leukemias, Training Program in Molecular Hematology
OpenAlex ID: W4200484367
